G E Tsai

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Glutamatergic mechanisms in schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, USA
    Annu Rev Pharmacol Toxicol 42:165-79. 2002
  2. ncbi request reprint Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience GT, McLean Hospital and Harvard Medical School, Boston, Massachusetts 02478, USA
    Biol Psychiatry 55:452-6. 2004
  3. ncbi request reprint A preliminary study of D-cycloserine treatment in Alzheimer's disease
    G E Tsai
    Geriatric Neurobehavioral Clinic, Massachusetts General Hospital, Charlestown, USA
    J Neuropsychiatry Clin Neurosci 10:224-6. 1998
  4. ncbi request reprint Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal
    G E Tsai
    Department of Psychiatry, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 155:726-32. 1998
  5. ncbi request reprint Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
    G E Tsai
    Geriatric Neurobehavoral Clinic, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Am J Psychiatry 156:467-9. 1999
  6. ncbi request reprint A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
  7. ncbi request reprint The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 174:32-8. 2004
  8. ncbi request reprint Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
    Joseph T Coyle
    McLean Hospital, Belmont, Massachusetts 02478, USA
    Ann N Y Acad Sci 1003:318-27. 2003
  9. ncbi request reprint Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    Joseph T Coyle
    Curr Drug Targets CNS Neurol Disord 1:183-9. 2002
  10. ncbi request reprint D-serine added to clozapine for the treatment of schizophrenia
    G E Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA
    Am J Psychiatry 156:1822-5. 1999

Detail Information

Publications17

  1. ncbi request reprint Glutamatergic mechanisms in schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, USA
    Annu Rev Pharmacol Toxicol 42:165-79. 2002
    ..Thus, hypofunction of a subpopulation of cortico-limbic NMDA receptors may participate in the pathophysiology of schizophrenia...
  2. ncbi request reprint Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
    Guochuan Tsai
    Laboratory of Molecular and Psychiatric Neuroscience GT, McLean Hospital and Harvard Medical School, Boston, Massachusetts 02478, USA
    Biol Psychiatry 55:452-6. 2004
    ..N-methylglycine (sarcosine) is an endogenous antagonist of glycine transporter-1, which potentiates glycine's action on N-methyl-D-aspartate glycine site and can have beneficial effects on schizophrenia...
  3. ncbi request reprint A preliminary study of D-cycloserine treatment in Alzheimer's disease
    G E Tsai
    Geriatric Neurobehavioral Clinic, Massachusetts General Hospital, Charlestown, USA
    J Neuropsychiatry Clin Neurosci 10:224-6. 1998
    ..This double-blind crossover study of 15 mg D-cycloserine in Alzheimer's disease patients did not demonstrate clinical benefit. Higher medication dosage or long-term treatment may be required...
  4. ncbi request reprint Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal
    G E Tsai
    Department of Psychiatry, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 155:726-32. 1998
    ..Whether glutamatergic neurotransmission and oxidative stress are enhanced during ethanol withdrawal in humans is unknown...
  5. ncbi request reprint Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
    G E Tsai
    Geriatric Neurobehavoral Clinic, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, USA
    Am J Psychiatry 156:467-9. 1999
    ..D-Cycloserine exhibits partial agonist activity at the glycine site of N-methyl-D-aspartate subtype glutamate receptor, facilitating activation of the receptor and improving cognition and memory...
  6. ncbi request reprint A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Mass, USA
    Psychopharmacology (Berl) 179:144-50. 2005
    ..The strongest evidence for efficacy has come from studies using D-cycloserine at a dose of 50 mg/day added to conventional antipsychotics in trials of 8 weeks duration or less...
  7. ncbi request reprint The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, MA 02478, USA
    Psychopharmacology (Berl) 174:32-8. 2004
    ..Thus, there is convincing evidence that the glycine modulatory site on the NMDA receptor is a valid therapeutic target for improving cognition and associated negative symptoms in schizophrenia...
  8. ncbi request reprint Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia
    Joseph T Coyle
    McLean Hospital, Belmont, Massachusetts 02478, USA
    Ann N Y Acad Sci 1003:318-27. 2003
    ..Thus, there is convincing evidence that hypofunction of a subset of NMDA receptors may contribute to the symptomatic features of schizophrenia...
  9. ncbi request reprint Ionotropic glutamate receptors as therapeutic targets in schizophrenia
    Joseph T Coyle
    Curr Drug Targets CNS Neurol Disord 1:183-9. 2002
    ..Preliminary results with an allosteric modulator of the AMPA subtype of glutamate receptor suggest enhanced cognitive functions in subjects treated with clozapine...
  10. ncbi request reprint D-serine added to clozapine for the treatment of schizophrenia
    G E Tsai
    Laboratory of Molecular and Psychiatric Neuroscience, Mailman Research Center, McLean Hospital, Belmont, MA 02478, USA
    Am J Psychiatry 156:1822-5. 1999
    ..To study the difference between full and partial agonists at the NMDA receptor glycine site, the clinical effects of adding D-serine to clozapine were assessed...
  11. ncbi request reprint NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia
    Joseph T Coyle
    Department of Psychiatry, Harvard Medical School, McLean Hospital, Belmont, Massachusetts, USA
    Int Rev Neurobiol 59:491-515. 2004
  12. ncbi request reprint Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine
    Donald C Goff
    Schizophrenia Program, Massachusetts General Hospital, Boston, Massachusetts, USA
    Biol Psychiatry 51:493-7. 2002
    ..Recent evidence suggests that effects upon glutamatergic transmission may contribute to the therapeutic action of certain atypical antipsychotic agents...
  13. ncbi request reprint Elevated cerebrospinal fluid SNAP-25 in schizophrenia
    Peter M Thompson
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Biol Psychiatry 53:1132-7. 2003
    ..In this study, we explored SNAP-25 level and clinical variables in a new group of subjects...
  14. pmc Gene knockout of glycine transporter 1: characterization of the behavioral phenotype
    Guochuan Tsai
    Department of Psychiatry and Alcohol and Drug Abuse Research Center, McLean Hospital, Belmont, MA 02178, USA
    Proc Natl Acad Sci U S A 101:8485-90. 2004
    ....
  15. ncbi request reprint Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia
    Hsien Yuan Lane
    Department of Psychiatry, China Medical University and Hospital, Taichung, Taiwan
    Biol Psychiatry 60:645-9. 2006
    ..The present study aims to determine the effects of sarcosine adjuvant therapy for schizophrenic patients receiving clozapine treatment...
  16. ncbi request reprint Meta-analyses of the association between genetic polymorphisms of neurotrophic factors and schizophrenia
    Pao Yen Lin
    Department of Psychiatry, Chang Gung Memorial Hospital, Kaohsiung, Taiwan
    Schizophr Res 71:353-60. 2004
    ..These results suggested that the variations at the NT3 and the CNTF genes do not influence the schizophrenia risk, but a role in the susceptibility of subgroups of the patients cannot be excluded...
  17. pmc Reduced glycine transporter type 1 expression leads to major changes in glutamatergic neurotransmission of CA1 hippocampal neurones in mice
    Marzia Martina
    Departments of Cellular and Molecular Medicine, and Psychiatry, University of Ottawa, Ottawa, ON, Canada
    J Physiol 563:777-93. 2005
    ..Overall, these findings highlight the importance of GlyT1 in regulating glutamatergic neurotransmission...